Σημειώσεις επεισοδίου
Most LPs in this community underwrite things they can see. A rent roll, a cap rate, a debt schedule, a comp set two streets over. Biotech offers none of that. It asks you to fund a molecule that either works or does not, on a timeline you do not control, with no distributions along the way. So most passive investors skip the category entirely and call it a science problem.
The argument on this call is that it was never a science problem. By 2030, somewhere around $250 to $300 billion a year of branded drug revenue goes generic, the biggest patent cliff on record. Big pharma cannot invent its…
Ιστότοπος: podcasters.spotify.com

